Ascentage Pharma Group International - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AAPG Nasdaq 2836 www.ascentage.cn

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascentage Pharma Group International

Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know - Jul 27th, 2026 7:55 am
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - Jul 26th, 2026 5:30 pm
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23% - Jul 9th, 2026 7:55 am
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development - Jun 30th, 2026 7:20 am
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress - Jun 14th, 2026 5:30 pm
A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Weakness - Jun 8th, 2026 6:05 am
Ascentage Pharma (AAPG) Reports Phase 1b Olverembatinib Data - Jun 5th, 2026 3:03 pm
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 - May 31st, 2026 5:30 pm
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 - May 31st, 2026 5:30 pm
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 - May 31st, 2026 5:30 pm
Global Growth Companies Insiders Favor With Up To 40% Earnings Growth - May 25th, 2026 3:35 am
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 - May 21st, 2026 6:00 pm
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress - May 12th, 2026 8:15 pm
Ascentage Pharma to Participate in Three Upcoming Investor Conferences - May 12th, 2026 6:00 am
Global Growth Companies With High Insider Ownership In April 2026 - Apr 22nd, 2026 3:35 am
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 - Apr 21st, 2026 6:00 pm
Global Growth Companies With High Insider Ownership - Apr 20th, 2026 3:35 am
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting - Apr 19th, 2026 6:00 pm
Global Insights Into 3 Growth Stocks With High Insider Ownership - Apr 17th, 2026 3:36 am
Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer Says - Mar 27th, 2026 9:26 am